Verified factor-similar pair

JMOM vs XMMO

These two ETFs meet the same FF6 US comparison criteria: US-listed equity ETFs, the same USD model basis, at least one material non-market factor, and 100% overlap in statistically significant material factor exposure.

UMD
Similarity score
87
Verified similar

The score combines exposure-level distance, factor-vector shape, market-beta closeness, and a small backtested relative-Sharpe term.

Quick Read

  • XMMO has the higher backtested relative Sharpe (1.282 vs 1.203).
  • JMOM has the lower published fee (0.12% vs 0.35%).
  • XMMO is cheaper on dividend valuation (111 vs 127, where 100 is each fund's historical median).
  • JMOM has the stronger regression fit (adjusted R-squared 0.958 vs 0.840).

These are screening signals, not a complete review of portfolio construction, turnover, taxes, or trading quality.

JMOM

JPMorgan U.S. Momentum Factor ETF
UMD
Adj. R2
0.958
Rel. Sharpe
1.203
Mkt beta
1.03
AUM
US$2.1B
MER
0.12%
Valuation
127

XMMO

Invesco S&P MidCap Momentum ETF
UMD
Adj. R2
0.840
Rel. Sharpe
1.282
Mkt beta
1.05
AUM
US$6.4B
MER
0.35%
Valuation
111

Factor Exposure Match

Blue bars compare raw factor beta magnitude. Green bars compare absolute t-stat strength. Dim bars indicate the t-stat is below 1.96.

SMB
JMOM
+0.05
|t|
+1.1
XMMO
+0.37
|t|
+6.3
diff -0.32
HML
JMOM
-0.05
|t|
-1.4
XMMO
-0.10
|t|
-1.7
diff +0.05
RMW
JMOM
-0.06
|t|
-1.3
XMMO
-0.00
|t|
-0.0
diff -0.06
CMA
JMOM
-0.03
|t|
-0.5
XMMO
-0.04
|t|
-0.4
diff +0.01
UMD
JMOM
+0.21
|t|
+7.0
XMMO
+0.21
|t|
+6.1
diff -0.00

Why This Pair Matches

Exposure level
87
Exposure shape
84
Mkt beta diff
0.02
Rel. Sharpe diff
0.080

This comparison focuses on measured factor exposure. It does not compare holdings methodology, turnover, tax handling, or issuer process. Backtested relative Sharpe is a secondary signal rather than a stand-alone forecast. See methodology.

JMOM fund page XMMO fund page US ETF Leaders US Universe
Important context

VerifiedBeta publishes educational ETF research, not personalized investment advice, portfolio management, or security recommendations. Funds that screen well here can still be unsuitable for your objectives, taxes, liquidity needs, or constraints. Review fund documents, methodology assumptions, and your own circumstances before acting. See the full disclaimer.